Exudative age-related macular degeneration is leading cause of irreversible vision loss in developed countries. Subfoveal localisation of choroidal neovascular membrane is the most difficult form for treatment. At the last three years, the new group of agens well-known as anti-VEGF agens was approved for treatment of exudative AMD. In that purpose, intravitreally administrated agens is recommended. Efficacy and safety of anti-VEGF agens were proved in short-time follow up period.
C.H. M, S. M, J.C. S, P K. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularization secondary to age-related macular degeneration. Br J Ophthalmol. 90:1207–8.
2.
E.S. G, A.P. A, E.T.Jr. C. VEGF Inhibition study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 351:2805–16.
3.
P.J. R, D.M. B, J.S. H. MARINA study group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 355:1419–31.
4.
D.M. B, P.K. K, M. M. ANCHOR study group. Ranibizumab versus verteporfirin for neovascular age-related macular degeneration. N Engl J Med. 355:1432–44.
5.
J. S, R.I. A, G. H. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin. Retina. 26:262–9.
6.
P.J R. Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol. 142:141–3.
7.
P.J. R, A.A M. Puliafito C.A.: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 36:331–5.
8.
E.M S. A very effective treatment for neovascular macular degeneration. N Engl J Med. 355:1493–5.
9.
R.M. R, P.J. R, C.A. P. Short-time safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 26(5):495–511.
10.
R.F. S, K. L, H.F. F. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 26(4):383–90.
11.
N. E, T K. Holz F.G.: Pharmacological approaches to age-related macular degeneration.
12.
J.I L. The pros and cons of bevacizumab therapy for subfoveal choroidal neovascularization for age-related macular degeneration. Medscape Ophthalmology. 6(2).
13.
R.P.A. M, G.A. P, P. K. Testing intravitreal toxicity of bevacizumab (Avastin. Retina. 26(3):257–61.
14.
S. L, R. N, L.E. M. Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells. Retina. 26(5):512–8.
15.
M.S. S, B. WT, A. S. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 90:1316–21.
16.
S.J. B, J.D. C, C.A. M. Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model. Am J Ophthalmol. 142(1):162–4.
17.
F. Z, I.M. N, M. L. Does intravitreal injection of bevacizumab have an effect on the blood-aqueous barrier function? Br J Ophthalmol. 90(922).
18.
R.L. A, J. P, D.J. P. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 113(1695):1–15.
19.
S. G, S. B, S. P. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol. 142(1):158–60.
20.
F.H. D, J.G M. Derick R.J.: Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina. 26(3):354–6.
21.
R.L. E, M. K, Choriocarcinoma. Transfilter stimulation of vasoproliferation in the hamster cheek pouch. Studied by light and electron microscopy. J Natl Cancer Inst. 41:1329–41.
22.
S. R, D. P, D. E. Global data on visual impairment in the year 2002. Bull World Health Organ. 82:844–51.
23.
R. K, B.E K. Linton K.I.: Prevalence of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 99:933–43.
24.
S. M, P.J. R, C.A. P. Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration. Ophthalmology. 112:1035–47.
25.
Age-related Eye Disease Study (AREDS) Research Group: Potential risk health impact of Age-Related Eye Disease Study results: AREDS Report No.11. Arch Ophthalmol. 121:1621–4.
26.
Eye Diseases Prevalence Research Group: Causes and prevention of visual impairment among adults in the United States. Arch Ophthalmol. 122:477–85.
27.
Eye Disease Prevalence Research Group: The prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 122:564–72.
28.
Sickenberg M. Early detection, diagnosis and management of choroidal neovascularization in age-related macular degeneration: the role of ophthalmologists. Ophthalmologica. 215:247–53.
29.
R.F S. Aetilogy of Late Age-Related Macular Disease.
30.
U. C, G. S, F. B. Evolving European guidance on the medical management of neovascular age-related macular degeneration. Br J Ophthalmol. 90:1188–96.
31.
D.S. F, B.J. O ’Colmain, B. M. Prevalence of age-related macular disease in the United States. Arch Ophthalmol. 122:564–72.
32.
M. G, P S. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transplant chamber technique. J Natl Cancer Inst. 41:111–24.
33.
D.R. S, S.J. G, A.M. D. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:983–5.
34.
N. F, W.J H. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Commun. 161:851–8.
35.
Y.F. B, A. B, A. S. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 142:1–9.
36.
N. E, T.U K. Holy F.: New pharmacologic approaches to therapy for age-related macular degeneration. Biodrugs. 20(3):168–79.
37.
R.L. A, D.J. P, M.D. R. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 113:363–72.
38.
Sickenberg M. Early detection, diagnosis and management of choroidal neovascularization in age-related macular degeneration: the role of ophthalmologists. Ophthalmologica. 215:247–53.
39.
T.R. K, J.I L. Anti-VEGF treatment for age-related macular degeneration.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
